Printer Friendly

BenevolentAI signs exclusive license for series of novel clinical stage drug candidates with Janssen Pharmaceutica.

M2 PHARMA-November 10, 2016-BenevolentAI signs exclusive license for series of novel clinical stage drug candidates with Janssen Pharmaceutica

(C)2016 M2 COMMUNICATIONS

BenevolentAI, a United Kingdom-based artificial intelligence (AI) company, has signed an exclusive license for a series of novel clinical stage drug candidates with Janssen Pharmaceutica, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, it was reported yesterday.

The contract was facilitated by the Johnson & Johnson Innovation Centre in London.

BenevolentAI has acquired a license to a select number of novel clinical stage drug candidates and their extensive related range of patents. The company's scientists leveraged the AI technology to assess the potential of these small molecule compounds. The results suggest that there is the strong promise for the development of new medicines for hard to treat diseases. According to the terms of the license agreement, BenevolentAI will have the sole right to develop, manufacture and commercialise these novel drug candidates in all indications and in all territories. This contract will allow BenevolentAI to accelerate its development pipeline and use its unique artificial intelligence technology to explore and offer a rich source of clinical data. BenevolentAI plans to start late stage Phase IIb clinical trials in mid- 2017. Financial terms were not revealed.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2016 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2016 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Nov 10, 2016
Words:216
Previous Article:Aradigm reports higher net loss of USD8.2m for Q3 2016.
Next Article:RegeneRx admits first patients in Phase 3 US dry eye clinical trial with RGN-259.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters